



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 47/48</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/01758</b>  <b>(43) International Publication Date:</b> 21 February 1991 (21.02.91)
<b>(21) International Application Number:</b> PCT/EP90/01261 <b>(22) International Filing Date:</b> 26 July 1990 (26.07.90)  <b>(30) Priority data:</b> 8918009.5                      7 August 1989 (07.08.89)      GB 8919618.2                      30 August 1989 (30.08.89)      GB  <b>(71) Applicant (for all designated States except US):</b> DEBIO-PHARM S.A. [CH/CH]; 2, rue du Crêt, CH-1006 Lausanne (CH).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> VERONESE, Francesco [IT/IT]; SARTORE, Luciana [IT/IT]; Università di Padova, Via Marzolo, 5, I-35100 Padova (IT). ORSOLINI, Piero [IT/CH]; 11, rue de l'Hôpital, CH-1920 Martigny (CH). DEGHENGLI, Romano [IT/CH]; Chesaux Des-sus B 1, CH-1264 S.-Cergue (CH).		<b>(74) Agent:</b> VUILLE, Roman; Debiopharm S.A., P.O. Box 446, CH-1001 Lausanne (CH).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> BIOLOGICALLY ACTIVE DRUG POLYMER DERIVATIVES		
<b>(57) Abstract</b>  New biologically active drug polymer derivatives, namely peptides or protein derivatives, are useful medicaments and are represented by the generic formula: $RO-(CH_2-CH_2O)_n-(CO)-NH-X-(CO)-NH-Z$ , wherein R represents a lower alkyl group, n is an integer comprised between 25 and 250, X when combined with adjacent NH and CO groups represents an amino acid or a dipeptide or tripeptide residue, and Z when combined with the adjacent NH group represents a biologically active peptide or protein or NH or NH <sub>2</sub> containing drug residue.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

## Biologically active drug polymer derivatives

The invention relates to new biologically active drug polymer derivatives, namely, peptides or protein derivatives useful as medicaments. It relates more particularly to peptide or protein polyethylene glycol derivatives wherein the peptide or protein moiety is linked to the polyethylene glycol residue by means of an amino acid or peptide spacer arm.


Modification of biologically active substances such as peptides or proteins with monomethoxy polyethylene glycol is reported to change extensively their physical, chemical, enzymological, immunological, as well as their pharmacological and pharmacokinetic properties. Several methods to achieve such a modification have so far been reported (see e.g. US Patents 4.179.337 and 4.766.106; Appl. Biochem and Biotechnology, Vol. 11, p. 141/1985).

Such modified peptide or protein derivatives exhibit some advantages when compared to the peptide or protein itself: increased water solubility, decreased antigenicity or increased half-life of the circulating peptide or protein.

The use of such modified bioactive compounds, however, is not satisfying as the following drawbacks have been observed : difficulty to obtain a selective incorporation of a radioactive probe into the polymer drug adduct necessary for pharmacokinetic experiments; inactivation of some enzymes; difficulty to program (or to modulate) the cleavage of the polymer-protein bond by specific enzymes in the body; difficulty of introduction into the polymer-drugs adduct amino acid sequences which may confer targeting properties to the adducts itself. These disadvantages are related to the chemistry employed in the polymer activation and to its direct linkage to the drug.

- 2 -

It has been found that some, if not all of the above mentioned drawbacks can be eliminated or at least significantly reduced by making use of the new drug polymer derivatives of the invention which are represented by the generic formula



wherein

- R represents a lower alkyl group,  
n is an integer comprised between 25 and 250,  
X when combined with adjacent NH and CO groups represents an amino acid or a dipeptide or tripeptide residue, and  
Z when combined with the adjacent NH group represents a biologically active peptide or protein or NH or NH<sub>2</sub>-containing drug residue.

Preferred species of compounds of formula (I) are those wherein R represents a methyl group and wherein n is an integer comprised between 40 and 115, i.e. those of which the polyethylene moiety exhibits a molecular weight of about 1800 to 5500, for example of 1900 and 5000

Also preferred are the compounds of formula (I) wherein symbol X when combined with the adjacent NH and CO groups represents an amino acid selected from glycine, phenylalanine, tryptophan and norleucine, or a dipeptide or tripeptide such as Gly-Gly, Arg-Arg, Phe-Arg, Gly-Gly-Arg, Gly-Gly-Phe or Gly-Leu-Gly-Leu.

Also preferred are the compounds of formula (I) wherein symbol Z, when combined with the adjacent NH group represents the residue of a biologically active peptide, protein or drug, selected from the following species :

- enzymes such as superoxidedismutase, ribonuclease, arginase, asparaginase, urokinase, e.g.;

- 3 -

- antibiotics such as ampicillin, doxorubicin e.g.;
- synthetic drugs like N-desmethyl-tamoxifen;
- peptides such as LHRH and synthetic analogues of same, somatostatin and synthetic analogues of same, e.g.;
- proteins such as interleukin-2, tumor necrosis factor, insulin, IGF-1 e.g.;
- nucleosides such as adenin-arabinoside (ara-A), cytosin-arabinoside (ara-C), acyclovir e.g.

This enumeration is in no way limitative.

Some but not all of the most interesting peptide derivatives of formula (I) are mentioned and characterized individually in the Examples.


Consequently, the invention relates to new biologically active peptide derivatives of formula (I) as defined above, as well as to a method for preparing same.

The invention also relates to pharmaceutical compositions which comprise at least one of the compounds of formula (I) as active ingredient. Further objects of the invention shall appear from the specification or the claims.

The method of the invention is based on the linkage of an amino acid or peptide spacer arm of various structures and properties to the hydroxyl function of monoalkoxy-polyethylene glycol through a carbonate linkage which involves the  $\text{NH}_2$  group of the amino acid or peptide. This reaction is followed by the activation of the  $\text{COOH}$  function of the amino acid or peptide spacer arm as succinimidyl ester which, thus, becomes reactive towards the amino group of the biologically active peptide, protein or drug.

More specifically the method of the invention consists of :


- a) reacting a mono-alkoxy-polyethylene glycol derivative of formula




- 4 -

wherein R and n have the definition provided above, with 2,4,5-trichlorophenylchloroformate or 4-nitrophenylchloroformate to obtain the corresponding carbonate;

- b) reacting the carbonate thus obtained with an amino acid or a di- or tripeptide of formula



wherein X is defined above to obtain a compound of formula



- c) converting the compound of formula (IV) thus obtained into the corresponding succinimidyl ester, and
- d) finally, reacting the said succinimidyl ester with a biologically active peptide or protein or NH or NH<sub>2</sub>-containing drug of formula



wherein R and Z are defined as indicated above.

Steps a) through d) of the above described method do not necessitate special reaction conditions and can be carried out according to the usual techniques. Details of each of the above reaction steps are provided in the Examples illustrating the invention.

By means of the introduction of such a new spacer arm (amino acid or peptide) an improved targeting of the bioactive protein or drug is achieved : an enhanced lysosomal degradation of the peptide derivative of formula (I), a site-specific cleavage of the derivative by specific

- 5 -

cellular enzymes as well as, in some instances, an increased binding of the derivative to specific cellular receptors which recognize the amino acid moiety.

There are still additional advantages : the new spacer arm may contain a residue which can be conveniently used to quantitate directly the polymer chains introduced into the protein. This can be performed by UV absorption in the case of tryptophan or phenylalanine, or by amino acid analysis in the case of norleucine which is not naturally present in proteins from natural sources.

The spacer arm may also be made radioactive using labelled amino acids, which simplifies to a great extent the detection of the biologically active peptide derivative during pharmacokinetic or metabolic experiments.

Some of these interesting properties are illustrated in the following Examples which are not limitative. In the said Examples the term "M-PEG" defines a monomethoxy-polyethylene glycol and the amino acids or peptides are described by means of the terms usual in the art.

#### A. Preparation of activated M-PEG with an amino acid or peptide spacer arm.

##### Example 1

##### M-PEG 5000-Gly-Succinimidyl ester (M-PEG 5000-Gly-OSu)

To 10 g (2mM) of M-PEG-5000, dissolved in 50 ml of anhydrous methylene chloride, 0.56 ml (4mM) of triethylamine (TEA) and 0.81 g (4 mM) of 4-nitrophenyl chloroformate were added under stirring while the pH was adjusted at 7.5-8.0 with TEA. The reaction mixture was maintained at room temperature for 4 hrs. The mixture, concentrated under vacuum to about 10 ml, was dropped into 200 ml of stirred diethyl ether. The precipitate was collected by filtration and crystallized twice from hot ethyl acetate. The yield of M-

- 6 -

PEG-p-nitrophe-nylcarbonate (M-PEG-OCO-O-Ph-NO<sub>2</sub>), calculated spectrophotometrically on the basis of p-nitrophenol absorption was over 95%.

Glycine 1.5 g (20 mM) were dissolved in 20 ml of water, the solution was adjusted to pH 8.0-8.3 and added under stirring of 10.33 g (2 mM) of M-PEG-OCO-O-Ph-NO<sub>2</sub> while the pH was maintained at 8.3 with NaOH. After 4 hrs at room temperature the solution, cooled at 0°C and brought to pH 3 with 2N HCl, was extracted three times with CHCl<sub>3</sub>. The chloroform was washed with water, dried with Na<sub>2</sub>SO<sub>4</sub>, concentrated, precipitated with diethyl ether and the precipitate recrystallized from ethanol. The yield, calculated by COOH titration and glycine evaluation by conventional amino acid analysis after acid hydrolysis, was 85%.

M-PEG-Gly-OH 10.2 g (2mM) was dissolved in 50 ml of anhydrous methylene chloride, cooled to 0°C, and 0.46 g (4 mM) of N-hydroxysuccinimide and 0.83 g (4 mM) of N,N-dicyclohexylcarbodiimide were added under stirring. The stirring was continued for 4 hrs, while the temperature was raised to 20°C. The precipitated dicyclohexylurea was removed from the reaction mixture by filtration, the solution was concentrated under vacuum and the product precipitated with diethyl ether and recrystallized from ethyl acetate. The yield of esterification, calculated from the UV hydroxysuccinimide absorption, was 85 %.

Starting from M-PEG 1900 the M-PEG-1900-Gly-OSu derivative was obtained following the same procedure with a similar yield.

#### Example 2

##### M-PEG 5000-Trp-succinimidyl ester (M-PEG 5000-Trp-OSu)

The procedure described above gave the PEG-tryptophan derivative with a yield of 80% calculated on the



- 7 -

basis of the hydroxysuccinimide absorption as well as the tryptophan absorption at 280 nm (Fig. 1a).

- The product presented the characteristic tryptophan absorption spectra as reported in Fig. 1.

#### Example 3

##### M-PEG 5000-Phe-succinimidyl ester (M-PEG 5000-Phe-OSu)

Following the procedure reported in Example 1 the M-PEG phenylalanine derivative was obtained. The product gave the spectra reported in Figure 2 with the typical phenylalanine absorption at 260 nm (Fig. 2a).

#### Example 4

##### M-PEG-nor-Leu-succinimidyl ester (M-PEG-5000-nor-Leu-OSu)

This derivative was obtained as above described with both M-PEG 5000 and M-PEG 1900. The 95% yield was calculated by nor-Leu evaluation on an amino acid analyzer after acid hydrolysis.

#### Example 5

##### M-PEG 5000-Gly-Gly-succinimidyl ester (M-PEG-5000-Gly-Gly-OSu)

Using Gly-Gly as a model compound, the procedure already described under Example 1 was followed to prepare an activated monomethoxy polyethylene glycol with a dipeptide as a spacer arm. The product, crystallized from ethyl acetate, was obtained with a 85% yield.

**B. Bioactive substances modification with amino acid derivatized M-PEG.**

- 8 -

Example 6Superoxide dismutase modification**6.1. With M-PEG 5000-Gly-OSu.**

Yeast superoxide dismutase (SOD, EC 1.15.1.1.) (100 mg) were dissolved in 10 ml of borate buffer 0.2M pH 8 and 640 mg of M-PEG 5000-Gly-OSu were added at room temperature under vigorous stirring while the pH was maintained. The mixture was left standing for 30 min.

The extent of linked polymer chains, determined on the basis of amino groups modification evaluated according to the method of trinitrophenylation of Snyder and Sabocinski (Snyder S.I. and Sabocinsky P.Z., Anal. Biochem. **64** 248-288, 1975) was over 85-90% while a 20 % reduction in enzymatic activity was observed. The enzyme was evaluated by the method of Paoletti et al. (Paoletti F., Aldinucci D. Mocali A. and Caparrini A., Anal. Biochem. **154** 536-541, 1986).

The excess of polymer was removed by twice ultrafiltration on a PM 10 AMICON membrane and the concentrated enzyme chromatographed on a BIO-GEL A 0.5 m column. The M-PEG modified enzyme is eluted first as symmetrical peak as revealed by UV absorption (Fig. 3a), iodine reaction for M-PEG and enzymatic activity. The excess of M-PEG is eluted later followed by the leaving group hydroxysuccinimide. The protein peak fractions are collected and lyophilized after membrane ultrafiltration. The M-PEG modified SOD is stored at 0°C in a dessicator.

**6.2 - With M-PEG-5000-Trp-OSu**

The reaction was carried out as reported above (see 6.1); a similar extent of linked polymer chains to SOD and enzyme activity reduction was observed while the product presented the spectrum reported in Fig. 3 where the contribution of tryptophan is evident.

- 9 -

### 6.3 - With M-PEG 5000-nor-Leu-OSu

The reaction carried out as reported in 6.1 gave a product with similar enzymatic properties and extent of modification by TNBS assay. In this case the amino acid analysis after acid hydrolysis revealed the presence of nor-leucine which accounted for 18 M-PEG chains bound to each SOD molecule in agreement with the TNBS test.

### 6.4 - With M-PEG 1900-Gly-OSu

The reaction was carried out as in 6.1, similar results were obtained as far as polymer linkage and enzymatic activity is concerned, this product is eluted later from the column as expected from the lower molecular weight of the polymer used in the modification.

Comment to examples 6.1 through 6.4: the purification from unreacted M-PEG 5000 or M-PEG 1900 could be successfully reached by dilution of the reaction mixture (about 1 to 10 folds) followed by ultrafiltration concentration on an AMICON membrane; this procedure of dilution and ultrafiltration must be repeated at least 4 times.

### Pharmacokinetic behavior of native and M-PEG-modified SOD

Unmodified yeast superoxide dismutase (5.5 mg) or equiactive amount of SOD modified with M-PEG 5000-Gly or M-PEG 1900-Gly were injected into the tail vein of Wistar albino male rats.

On a scheduled time the blood was removed by heart puncture with heparinized syringe and SOD evaluated in the plasma on the basis of its enzymatic activity. Before activity evaluation in plasma was purified from interferences by CM cellulose and SEPHADEX G 25 column chromatography. A 50 % clearance of 6 min, 15 and 28 hrs was

- 10 -

respectively found for the native, the M-PEG 1900 and M-PEG 50000 modified derivatives.

### Enzymatic properties

The stability of the M-PEG 1900 and M-PEG 5000 modified yeast superoxide dismutase to different conditions are as follows :

- a. The M-PEG modified enzyme is less stable to incubation in a protein denaturant such 2M guanidinium chloride; after 4 hrs its residual activity is 10 % in comparison to the 20% of the native enzyme.
- b. The M-PEG 5000-Gly-SOD was maintained in water at a concentration of 1 mg/ml at 0°, 20° or 35°C. No loss of activity was found for at least 8 days incubation. The stability was also observed after 8 days standing at 20°C at a concentration as low as 0.01 mg/ml.

The M-PEG 5000-Gly-SOD was found to be stable to repeated freezing and thawing cycles.

A M-PEG enzyme solution was evaporated to dryness at low temperature under vacuum, dissolved and again concentrated; the M-PEG modified enzyme was stable for at least six of such cycles while the unmodified enzyme lost at least 15 % of its activity under the same conditions.

The M-PEG 5000-Gly-SOD was completely stable to repeated cycles of dissolution and lyophilization whereas the free enzyme at each treatment lost about 5% of its activity.

- 11 -

The M-PEG 5000-Gly-SOD, in the presence of metal chelates, was found to lose with greater difficulty the metals essential for the activity as compared to the free enzyme.

#### Example 7

##### Arginase modification (M-PEG 5000-Gly-arginase

Bovine liver arginase (EC 3.5.3.1), 100 mg, highly purified according to literature to give a specific activity of 1900 IU/mg, was dissolved in 15 ml of carbonate buffer pH 8.5, 0.2 M and 800 mg of M-PEG 5000-Gly-OSu were added under vigorous stirring while the pH was maintained by a pH-stat with NaOH 0.1 N in a microburette. After 30 minutes the solution was diluted to 50 ml with water and ultrafiltered at 4°C with an AMICON PM 10 ultrafiltration membrane to reduce the volume to about 5 ml. The M-PEG modified arginase was purified from excess reagent and by-products of reaction through column chromatography as reported in Example 1. The binding of polymer was at the level of over 50 % of arginase amino groups while only a 5% reduction in arginase activity was detected.

##### Enzymatic and pharmacokinetic properties of M-PEG-5000-Gly-arginase

The modification increased the stability of the enzyme to the action of proteolytic enzymes such trypsin, chymotrypsin, elastase and subtilysin.

The pharmacokinetic behavior of native and PEG derivatized enzyme was evaluated in the rats as reported under example 6.1. A 50% clearance time of 1.5 and 8 hrs was respectively found for the unmodified and the polymer modified arginase.

- 12 -

Example 8Ribonuclease modification (M-PEG 5000-Gly-ribonuclease)

Ribonuclease A (EC 2.7.7.16) from bovine pancreas was modified and purified as in example 6.1. The amount of M-PEG-Gly-OSu used for the modification was at a molar ratio of 2.5:1 calculated on the available amino groups of the enzymes. The modification resulted in the covalent linkage of 11 molecules of polymer for ribonuclease molecule.

The modification is accompanied by an enzyme activity loss of about 10% as verified with cytidine-2',3'-cycle phosphate while the modified enzyme was found to be 50% active towards ribonucleic acid.

Example 9Urokinase modification (M-PEG-500-Gly-urokinase)

Urokinase (EC 3.4.4.a) from urine was modified and purified as reported under example 6.1. With this enzyme the modification was carried out using a molar ratio of activated polymer/protein amino group of 1:2. Under these circumstances about 10 molecules of polymer were linked to each urokinase molecule. The enzymatic activity evaluated on the lysis of thrombus was 30% of that of the native enzyme while its esterolytic activity, assayed on the synthetic substrate carbobenzoxy-lysine-O-nitrophenyl ester, was the same of the unmodified urokinase.

Example 10Ampicillin modification

## 10.1 - M-PEG 5000-Gly-Ampicillin

To a solution of ampicillin sodium salt, 50 mg (0,135 mM) in 5 ml of borate buffer 0,2 M pH 8, 600 mg (0,12 mM) of M-PEG 5000-Gly-OSu were added under vigorous stirring.

- 13 -

The reaction mixture was left standing for 20 min, then separated by excess of ampicillin and of side products of reaction by gel filtration chromatography on a BIO GEL P 60 100-200 mesh column. The M-PEG modified drug was eluted first as a symmetric peak as revealed the UV absorption of ampicillin and the iodine reaction for PEG.

The drug modified peak fractions were collected, concentrated by ultrafiltration and lyophilized. The product was crystallized from ethyl acetate with a 70% yield based on the starting ampicillin. The same product was also prepared by the procedure that is reported below.

#### 10.2 - M-PEG 5000-Gly-Ampicillin

Ampicillin sodium salt 100 mg (0.27 mM) were solved in 20 ml of N,N-dimethylformamide (DMF); 1.0 g (0.2 mM) of M-PEG 5000-Gly-OSu and 0.03 ml of 4-methylmorpholine (NMM) were added while pH was adjusted at 8-8.3 with NMM. The reaction mixture was maintained at room temperature under stirring for about 4 hrs and then concentrated to dryness under high vacuum. The residue was solved in 5 ml of CH<sub>2</sub>Cl<sub>2</sub> which were dropped in stirred diethyl ether (100 ml). The precipitate was removed by filtration and crystallized. The first crystallization was from hot ethyl acetate and the second one from hot methanol. The yield, based on the starting ampicillin, was 60 %.

#### Example 11

##### Doxorubicin modification (M-PEG 5000-Gly-doxorubicin)

To a solution of doxorubicin hydrochloride, 50 mg ( $8.6 \cdot 10^{-2}$  mM) of M-PEG 5000-Gly-OSu were added in portions. The mixture was left standing at room temperature under vigorous stirring; after 15 min the pH was adjusted at 7 with HCl 1 M and the product purified from free drug and the leaving group hydroxysuccinimid by gel filtration chromatography on a BIO GEL P 60 100-200 mesh column. The M-

- 14 -


PEG modified drug was eluted as a peak with the typical UV absorption of doxorubicine (OD 230 and 480 nm) and the expected iodine reaction for MPEG. The M-PEG 5000-Gly-doxorubicin fractions were collected, concentrated by ultrafiltration and lyophilized. The product was further purified by chromatography on a BIO GEL A 0.5 m column. The overall yield, based on the starting drug, was 50 %.



- 15 -

## CLAIMS

1. Biologically active drug polymer derivatives having the formula



wherein

- R represents a lower alkyl group,  
n is an integer comprised between 25 and 250,  
X when combined with adjacent NH and CO groups represents an amino acid or a dipeptide or tripeptide residue, and  
Z when combined with the adjacent NH group represents a biologically active peptide or protein or NH or NH<sub>2</sub> containing drug residue.


2. Drug polymer derivatives according to claim 1 wherein

- R represents a methyl group,  
n is an integer comprised between 40 and 115  
X when combined with adjacent NH and CO groups represents an amino acid residue selected from glycine, phenylalanine, tryptophan and norleucine, or a dipeptide or tripeptide residue selected from Gly-Gly, Arg-Arg, Phe-Arg, Gly-Gly-Arg, Gly-Gly-Phe, and Gly-Leu-Gly-Leu.  
Z when combined with the adjacent NH group represents the residue of a biologically active peptide, protein or drug selected from superoxidedismutase, ribonuclease, arginase, asparaginase, urokinase, ampicilline, doxorubicine, N-desmethyl-tamixofen, LHRH and synthetic analogues of same, somatostatin and synthetic analogues of same, calcitonin, interleukin-2, tumor necrosis factor, insulin, IGF-1, natural or recombinant interferon, adenine-arabioside (ara-A), cytosine-arabioside (ara-C) or acyclovir.

- 16 -


3. Method for preparing biologically active drug polymer derivatives having the formula (I) as defined in claim 1 which comprises

a) reacting a mono-alkoxy-polyethylene glycol derivative of formula




wherein R and n have the definition provided above, with 2,4,5-trichlorophenylchloroformate or 4-nitrophenylchloroformate to obtain the corresponding carbonate;

b) reacting the carbonate thus obtained with an amino acid or a di- or tripeptide of formula




wherein X is defined above to obtain a compound of formula



c) converting the compound of formula (IV) thus obtained into the corresponding succinimidyl ester, and

d) finally, reacting the said succinimidyl ester with a biologically active peptide or protein or NH or NH<sub>2</sub>-containing drug of formula



wherein R and Z are defined as indicated in claim 1.

- 17 -

4. Pharmaceutical composition which comprises as active ingredient at least one biologically active drug polymer derivative of formula (I) as defined in claim 1.

5. Pharmaceutical composition according to claim 4 which comprises as active ingredient a biologically active drug polymer derivative of formula (I) wherein

- R represents a methyl group,
- n represents an integer comprised between 40 and 115,
- X when combined with adjacent NH and CO groups represents an amino acid residue selected from glycine, phenylalanine, tryptophan and norleucine, a dipeptide or tripeptide residue selected from Gly-Gly, Arg-Arg, Phe-Arg, Gly-Gly-Arg, Gly-Gly-Phe and Gly-Leu-Gly-Leu,
- Z when combined with the adjacent NH group represents a biologically active peptide, protein or drug residue selected from superoxidedismutase, ribonuclease, arginase, asparaginase, urokinase, ampicilline, doxorubicine, N-desmethyl-tamoxifen, LHRH and synthetic analogues of same, somatostatin and synthetic analogues of same, calcitonin, interleukin-2, tumor necrosis factor, insulin, IGF-1 natural or recombinant interferon, adenine-arabino- side (ara-A), cytosine-arabinoside (ara-C) or acyclovir.

6. Pharmaceutical composition according to claim 5 which comprises as active ingredient a biologically active drug polymer derivative selected from the group consisting of

- M-PEG 5000-Gly-superoxidedismutase,
- M-PEG 5000-Trp-superoxidedismutase,
- M-PEG 5000-nor-Leu-superoxidedismutase
- M-PEG 1900-Gly-superoxidedismutase,

- 18 -

M-PEG 5000-Gly-arginase,  
M-PEG 5000-Gly-ribonuclease,  
M-PEG 5000-Gly-urokinase,  
M-PEG 5000-Gly-ampicillin, and  
M-PEG 5000-Gly-doxorubicin

wherein M-PEG represents monomethoxy-polyethylene.

FIG. 1




FIG. 1a




FIG. 2




FIG. 2a




FIG. 3





FIG. 3a



# INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 90/01261

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC <sup>5</sup> : A 61 K 47/48		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC <sup>5</sup>	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X,Y	WO, A, 87/00056 (CETUS) 15 January 1987 see page 12, line 22 - page 13, line 4; claims (cited in the application) --	1-6
X	EP, A, 0247860 (CETUS) 2 December 1987 see page 5, lines 5-7; claims --	1-6
A	EP, A, 0304311 (THE WELCOME FOUND.) 22 February 1989 see page 4, line 47 - column 5, line 20; claims --	1-6
Y	EP, A, 0154432 (NIHON CHEM. RES. K.K.) 11 September 1985 see claims --	1-6
./.		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
13th November 1990	18. 12. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	<div style="display: flex; align-items: center; justify-content: center;"> <div style="font-family: cursive; font-size: 1.2em; margin-right: 10px;">M. Perz</div> <div style="border: 1px solid black; padding: 2px 5px;">M. PEIS</div> </div>	



III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	EP, A, 0098110 (NIHON CHEM. RES. K.K.) 11 January 1984 see page 3, line 16 - page 4, line 1; page 4, lines 2-12; claims --	1-6
A	STN Server, (Karlsruhe), AN no. CA108(14):118895x, A.J. Garman et al.: "The preparation and properties of novel reversible polymer-protein conjugates. 2- omega.-Methoxypolyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activators", & FEBS Lett., 223(2), 361-5 see the abstract --	
X	STN Server, (Karlsruhe), AN no. CA98(19):157397f, E. Boccu et al.: "Coupling of monomethoxypolyethyleneglycols to proteins via active esters", & Z. Naturforsch., C: Biosci., 38C (1-2), 94-9 see the abstract -----	1-6

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9001261  
SA 38680

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 10/12/90  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8700056	15-01-87	AU-A- 5970086	30-01-87
		EP-A- 0229108	22-07-87
		JP-T- 62503171	17-12-87
		US-A- 4917888	17-04-90
		US-A- 4766106	23-08-88
-----			
EP-A- 0247860	02-12-87	AU-B- 595321	29-03-90
		AU-A- 7347987	03-12-87
		JP-A- 62289522	16-12-87
-----			
EP-A- 0304311	22-02-89	AU-A- 2142888	02-03-89
		JP-A- 1071490	16-03-89
-----			
EP-A- 0154432	11-09-85	JP-A- 60176586	10-09-85
-----			
EP-A- 0098110	11-01-84	JP-A- 58225025	27-12-83
		JP-A- 59059629	05-04-84
		US-A- 4609546	02-09-86
-----			